Skip to main navigation Skip to search Skip to main content

High-Sensitivity C-Reactive Protein Is Associated With Heart Failure Hospitalization in Patients With Metabolic Dysfunction-Associated Fatty Liver Disease and Normal Left Ventricular Ejection Fraction Undergoing Coronary Angiography

  • Xiao Dong Zhou
  • , Qin Fen Chen
  • , Giovanni Targher
  • , Christopher D. Byrne
  • , Michael D. Shapiro
  • , Na Tian
  • , Tie Xiao
  • , Ki Chul Sung
  • , Gregory Y.H. Lip
  • , Ming Hua Zheng
  • Wenzhou Medical University
  • University of Verona
  • IRCCS Sacro Cuore–Don Calabria Hospital
  • University Hospital Southampton NHS Foundation Trust
  • Wake Forest University
  • Kangbuk Samsung Hospital
  • University of Liverpool
  • Aalborg University
  • Key Laboratory of Diagnosis and Treatment for the Development of Chronic Liver Disease in Zhejiang Province

Research output: Contribution to journal › Article › peer-review

Abstract

BACKGROUND: Systemic chronic inflammation plays a role in the pathophysiology of both heart failure with preserved ejection fraction (HFpEF) and metabolic dysfunction-associated fatty liver disease. This study aimed to investigate whether serum hs-CRP (high-sensitivity C-reactive protein) levels were associated with the future risk of heart failure (HF) hospitalization in patients with metabolic dysfunction-associated fatty liver disease and a normal left ventricular ejection fraction. METHODS AND RESULTS: The study enrolled consecutive individuals with metabolic dysfunction-associated fatty liver disease and normal left ventricular ejection fraction who underwent coronary angiography for suspected coronary heart disease. The study population was subdivided into non-HF, pre-HFpEF, and HFpEF groups at baseline. The study outcome was time to the first hospitalization for HF. In 10 019 middle-aged individuals (mean age, 63.3±10.6 years; 38.5% women), the prevalence rates of HFpEF and pre-HFpEF were 34.2% and 34.5%, with a median serum hs-CRP level of 4.5 mg/L (interquartile range, 1.9–10 mg/L) and 5.0 mg/L (interquartile range, 2.1–10.1 mg/L), respectively. Serum hs-CRP levels were significantly higher in the pre-HFpEF and HFpEF groups than in the non-HF group. HF hospitalizations occurred in 1942 (19.4%) patients over a median of 3.2 years, with rates of 3.7% in non-HF, 20.8% in pre-HFpEF, and 32.1% in HFpEF, respectively. Cox regression analyses showed that patients in the highest hs-CRP quartile had a ≈4.5-fold increased risk of being hospitalized for HF compared with those in the lowest hs-CRP quartile (adjusted-hazard ratio, 4.42 [95% CI, 3.72–5.25]). CONCLUSIONS: There was a high prevalence of baseline pre-HFpEF and HFpEF in patients with metabolic dysfunction-associated fatty liver disease and suspected coronary heart disease. There was an increased risk of HF hospitalization in those with elevated hs-CRP levels.

Original languageEnglish
Article numbere032997
JournalJournal of the American Heart Association
Volume13
Issue number3
DOIs
StatePublished - 6 Feb 2024
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • heart failure hospitalization
  • heart failure with preserved ejection fraction
  • high-sensitivity C-reactive protein
  • metabolic dysfunction-associated fatty liver disease
  • metabolic dysfunction-associated steatotic liver disease

Fingerprint

Dive into the research topics of 'High-Sensitivity C-Reactive Protein Is Associated With Heart Failure Hospitalization in Patients With Metabolic Dysfunction-Associated Fatty Liver Disease and Normal Left Ventricular Ejection Fraction Undergoing Coronary Angiography'. Together they form a unique fingerprint.

Cite this